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Community-acquired pneumonia (CAP) is a leading 
cause of childhood morbidity and mortality, with an 
estimated global incidence of 0.22 episodes per child 
year in 2010 in low-and middle-income countries 
(LMICs).[1] Empyema is an important complication 
of CAP, with Streptococcus pneumoniae and Staphylococcus aureus 
leading causes. Although an increase in the incidence of empyema 
has been reported from some high-income countries following 
introduction of 7-valent pneumococcal conjugate vaccine (PCV7), 
the incidence of empyema in the USA following introduction of 
13-valent PCV (PCV13) has dropped by 50% in children <2 years of 
age.[2-4] In South Africa (SA), the incidence of invasive pneumococcal 
disease has similarly fallen following the introduction of PCV13 into 
the national immunisation programme in 2011.[5,6]
Intrapleural fibrinolytic therapy as first-line treatment of empyema 
has been reported in two randomised controlled trials in children. In 
a study in the UK, Thomson et al.[7] reported that urokinase resulted 
in a 2-day reduction in length of hospital stay compared with normal 
saline, but the rate of treatment failure was similar in both treatment 
groups. Singh et al.[8] compared streptokinase with normal saline and 
reported that the need for surgical decortication was higher at 30 days 
in the normal-saline groups. Intrapleural fibrinolysis as the primary 
intervention for empyema has an outcome equivalent to video-
assisted thorascopic surgery (VATS).[9] However, surgery, whether 
VATS or thoracotomy, is invasive and expensive, and requires specific 
expertise that is often unavailable in LMICs.[10]
There are no data on the efficacy of fibrinolytics in an African setting 
where the burden of childhood pneumonia is high and comorbid 
illness such as HIV infection, tuberculosis (TB) and malnutrition 
lead to more severe disease. The aim of this study was to compare the 
outcome of children with empyema before and after routine fibrinloysis 
was introduced at a tertiary paediatric hospital in SA in 2009.
Methods
Study design and setting
This was a prospective study of children sequentially hospitalised 
for empyema between December 2006 and December 2011 at Red 
Cross War Memorial Children’s Hospital (RCWMCH), a large public 
paediatric referral hospital in Cape Town, SA. Eligible patients were 
identified through direct referral to the pulmonology service and 
daily active surveillance of all admissions for empyema. Patient care 
was supervised by the same medical and surgical teams throughout 
the study period. 
Children with pleural effusion after surgery or trauma were 
excluded. Patients admitted directly to the paediatric intensive care 
unit on presentation were also excluded. Children presenting with 
confirmed, suspected or probable TB pleural effusions were not 
enrolled. However, those with TB presenting clinically as empyema 
where TB was not initially suspected but was confirmed by culture 
after the child received fibrinolytics were included in the treatment 
analysis.
Empyema definition and management 
Empyema was diagnosed if the pleural fluid met any of the 
following criteria: frank pus or turbid fluid on inspection; neutrophil 
predominance or pus cells present on microscopy; bacterial organism 
seen by Gram stain or isolated by culture; or loculated pleural 
collection on chest ultrasound. TB empyema was diagnosed if the 
pleural effusion met any of the above criteria and Mycobacterium 
tuberculosis was detected in the pleural fluid by direct microscopy or 
liquid culture.
Routine management of empyema included general supportive 
measures and broad-spectrum antibiotics for 14 days (intravenous 
followed by oral). Empirical intravenous ampicillin (50 mg/kg 
6-hourly) and cloxacillin (50 mg/kg 6-hourly) was the standard of care. 
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Children with suspected or proven staphylo-
coccal empyema were treated for 6 weeks 
with cloxacillin or the oral equivalent. An 
aminoglycoside (gentamycin 5 mg/kg/d) was 
added in children who were malnourished, 
HIV-infected or under 3 months of age, 
according to local guidelines. Antibiotics 
were adjusted according to clinical response 
and microbiological results. TB treatment 
was initiated in cases where TB co-infection 
was clinically suspected or microbiologically 
proven.
Before 2009, empyema was managed by 
chest tube drainage without fibrinloysis. In 
2009, a protocol for intrapleural fibrinolysis 
was introduced. The protocol and indications 
for chest tube insertion, fibrinloysis and 
referral for surgery are summarised in Fig. 1. 
A chest tube to drain the pleural space was 
inserted under sedation and local anaesthesia 
if any of the following were present: large 
pleural effusion causing symptoms (pain 
or tachypnoea) or mediastinal shift; turbid 
fluid or pus aspirated during pleurocentesis; 
pleural effusion associated with clinical signs 
of sepsis; pyopneumothorax; or effusion 
with persistent pyrexia (>48 hours) despite 
appropriate antibiotic treatment. Large hard-
bore chest tubes (10 - 14F gauge) attached to 
an underwater drainage system were initially 
the standard of care, but percutaneous pigtail 
catheters (12F gauge) became available in 
2010 and were subsequently preferentially 
used. 
After confirmation of the correct chest 
tube position by X-ray and exclusion of 
contraindications (Fig. 1), tissue plasmino-
gen activator (TPA) (Alteplase, Boehringer 
Ingelheim) was instilled into the pleura 
via the chest tube according to a standard 
protocol (Fig. 1) within 24 hours after inser-
tion of the chest tube. A dose of 4 mg TPA 
in 40  mL 0.9% saline (2 mg in 20 mL for 
children <5 kg) was instilled once a day for 
3 consecutive days (Fig. 1). 
Clinical data collection, 
investigations and outcomes
Clinical, aetiological and outcome data 
were prospectively collected. All patients 
had a chest X-ray done on admission. A 
chest ultrasound scan was requested at the 
discretion of the attending clinician. Pleural 
fluid, obtained by pleurocentesis or at the 
time of chest tube insertion, was sent for 
routine microscopy and bacterial culture. 
TB investigations, including a tuberculin 
skin test, gastric lavage and pleural fluid 
TB microscopy and culture, were performed 
when TB was clinically suspected and at the 
discretion of the attending clinicians. Analysis 
of the pleural fluid included total protein 
and lactate dehydrogenase where possible. 
A blood culture was performed routinely. 
HIV testing with consent was routinely 
done according to the current standard of 
care, unless the HIV status of the child was 
known. An HIV DNA polymerase chain 
reaction (Amplicor HIV-1 DNA test version 
1.5; Roche Diagnostics, GmbH, Germany) 
was done in those younger than 18 months, 
and an HIV enzyme-linked immunosorbent 
assay (ArchitectHIV Ag/Ab Combo ELISA; 
Abbott Laboratories, USA) in older children. 
A CD4 count was done in HIV-infected 
children. Weight-for-age z-scores (WAZs) 
(World Health Organization) were calculated 
for children <5 years of age; malnutrition was 
defined as a WAZ <–2.
The primary outcome was need for surgical 
intervention. The indications for surgical 
referral are described in Fig. 1. Secondary 
outcomes were length of hospital stay and 
in-hospital mortality. Complications relating 
to the underlying empyema and treatment-
related complications were also recorded. 
The study was approved by the Human 
Research Ethics Committee of the Faculty 
of Health Sciences, University of Cape Town 
(HREC 230/2009). 
Statistical analysis
Data were analysed using STATA (version 
10.0, Statcorp, USA). Continuous variables 
were expressed as means (standard deviation 
(SD)) for normally distributed variables or 
medians and interquartile ranges (IQRs) 
for non-normally distributed variables. 
The Mann-Whitney U-test was used for 
comparing non-normally distributed 
measures. Categorical variables were 
compared using the χ2 test. Relative risk 
(RR) and 95% confidence intervals (CIs) 
were calculated where applicable. 
Results
Clinical characteristics 
One hundred and forty-two children (59 in 
the pre-fibrinolysis period) with a median age 
of 17.4 months (IQR 8 - 43) were hospitalised 
Empyema diagnosed by dened crtiteria*
Routine investigations, empirical antibiotics and supportive care
Chest tube inserted or indicated?
Conservative medical
management and
observation
Contraindications to brinloysis
•  Pyopneumothorax/pneumatocele
•  Bleeding diathesis
•  TB empyema
Free drainage and observation onlyTPA 4 mg in 40 ml 0.9% saline instilled into pleural space
Drain clamped/closed to dwell for 1 hour
Drain unclamped/opened to low suction for 24 hours
TPA dose repeated daily for 3 consecutive days
TPA discontinued if:
• Adverse eects, e.g. excessive pleural bleeding
• Clinical deterioration
• Unintentional removal of chest tube with minimal
   residual pleural uid
Referred for surgery
Treatment failure
•  Persistent fever >38°C more than
   48 - 72 hours after drainage
•  Persistent or worsening symptoms,
   e.g. pain, tachypnoea
•  Inadequate drainage of residual uid
Continue routine care
Remove chest tube if clinical plus 
radiological improvement and:
•  No fever for 48 hours and
•  <30 ml pleural uid drainage/day
No
No
No
YES
YES
YES
Fig. 1. Chest tube and fibrinloysis protocol. (*Empyema definition: frank pus or turbid fluid; neutrophil 
predominance, pus cells or bacteria on microscopy; or loculated pleural collection on chest ultrasound scan.)
RESEARCH
551      July 2015, Vol. 105, No. 7
for empyema during the study period; 81 
(57.0%) were male. Most (n=112, 78.9%) 
were referred from a primary care setting 
and 30 (21.1%) from other hospitals. Sixty-
six/127 (52.0%) received oral, intramuscular 
or intravenous antibiotics prior to admission 
to RCWMCH. PCV immunisation status 
could not be determined in 11 cases; 6 
children were partially immunised and the 
remainder were unimmunised. Twenty-eight 
patients (19.7%) were HIV-infected, with a 
mean CD4 count of 18.4% (SD 9.5%), and 
44/114 children (38.6%) were malnourished. 
Pyopneumothorax was present in 22 cases 
(15.5%) and pneumatocele(s) in 9 (6.3%).
Empyema aetiology
The culture-positive rates of pleural fluid 
and blood culture were 45/142 (31.7%) and 
33/132 (25.0%), respectively (Table 1). The 
commonest bacterial pathogens identified 
on blood or pleural culture were S. aureus 
and S. pneumoniae (Table 1). Ninety and 
104 patients, respectively, had gastric lavage 
and pleural fluid investigated for TB. Overall, 
12/142 (8.4%) children had culture-confirmed 
TB, of whom 10/104 (9.6%) were diagnosed 
with TB empyema. Two additional cases of 
culture-confirmed TB were detected through 
gastric lavage cultures. Bacterial-TB empyema 
was confirmed by culture in 5 patients. 
Clinical course and outcome 
One hundred and thirty-five patients 
(95.1%) had a chest tube inserted and 9 
(6.6%) required two or more chest tubes 
during their hospitalisation. The median 
duration of chest tube placement was 5 days 
(IQR 3 - 10). Large-bore hard chest tubes 
were used in most patients (107, 79.3%) and 
pigtail catheters in 27 (20.0%), all in the TPA 
treatment group. Nineteen patients (13.4%) 
were referred to the intensive care unit. 
Overall, 29 (20.5%) patients needed surgery 
and 6 died in hospital (4.2%).
Excluding patients who did not have a 
chest tube inserted because their disease 
was mild and those in whom fibrinolysis 
was contraindicated (22 pyopneumothorax, 
9 pneumatoceles and 5 TB empyema), data 
on 99 patients from the pre- and post-
fibrinolysis periods (TPA 52, no TPA 47) 
were available for comparative analysis 
(Fig. 2). Baseline clinical characteristics and 
empyema aetiology were similar in the two 
groups (Table 2). Eighteen of 47 children 
(38.3%) not treated with fibrinolytics 
required surgery compared with 5/52 (9.6%) 
of those treated with TPA (RR 0.25; 95% 
CI 0.1 - 0.6). There was a trend towards 
shorter hospital stay in the TPA group, but 
the difference was not statistically significant 
(Table 3). Surgery, however, was associated 
with a longer hospital stay (median 16 
days (IQR 13 - 29) v. 12 days (IQR 8 - 17); 
p=0.001). The median time to surgery from 
admission was similar in the two groups 
(7 days each). Complications relating to 
empyema or treatment occurred rarely in 
both groups (Table 3). 
Compared with children who were 
eligible for fibrinolysis, a longer period of 
hospitalisation (median 18 days (IQR  11 - 
29) v. 12 days (IQR 8 - 16); p<0.01), more 
disease complications (10/32 (31.3%) 
v. 11/102 (10.8%); p<0.01) and a longer 
time to surgery (median 13 days (IQR 9 - 
20) v. 7 days (IQR 4 - 8); p=0.02) were 
observed in children in whom fibrinolysis 
was contraindicated. Six of these 36 patients 
(16.7%) needed surgery. Mortality was low 
and similar to the rest of the cohort (2/36 
(5.6%) v. 4/106 (3.8%); p=0.6).
Discussion
This study found a four-fold reduction 
in surgical intervention with the imple-
mentation of routine fibrinloysis using 
TPA in SA children with empyema. The 
results also suggest a trend towards shorter 
hospital stay and fewer chest drains in 
children receiving fibrinolytics. This is the 
first study describing the use of fibrinolytics 
in an African setting where the prevalence of 
childhood malnutrition, HIV and infectious 
diseases is high, as shown by the comorbidity 
Table 1. Bacterial isolates from pleural fluid and blood culture (N=142 patients)
Pleural fluid culture
Frequency  
n (%) Blood culture
Frequency  
n (%)
Staphylococcus aureus 19 (13.4) S. pneumoniae 18 (12.7)
Streptococcus pneumoniae 14 (9.9) S. aureus 9 (6.3)
Other streptococci 3 (2.1) H. influenzae 2 (1.4)
Staphylococcus aureus/Escherichia coli 1 (0.7) S. aureus/K. pneumoniae 1 (0.7)
Haemophilus influenzae 1 (0.7) S. pneumoniae/S. aureus 1 (0.7)
H. influenzae/E. coli 1 (0.7) S. hominis 1 (0.7)
Klebsiella pneumoniae 1 (0.7) Pantoea spp. 1 (0.7)
Anaerobes 1 (0.7) S. pyogenes 1 (0.7)
No growth 94 (66.2) No growth 98 (69.0)
Not done 7 (4.9) Not done 10 (7.0)
N=142 patients
n=7 excluded as no chest drain
n=135 patients
with chest drain
n=36 excluded as brinolytics
contraindicated
TPA n=52No TPA n=47
n=99 patients
Fig. 2. Study population selection.
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present in children. The prevalence of TB 
was nearly 10%, highlighting the importance 
of TB as an unrecognised cause of empyema 
in this setting.
These findings are consistent with other 
reports, mostly from high-income countries, 
despite the high rate of comorbid illness, 
including HIV and malnutrition, in children 
in our study. Several observational studies 
have compared the outcome of empyema 
in children treated with fibrinolytics (TPA, 
urokinase or streptokinase) with historical 
cohorts not treated with fibrinolytics. With 
the exception of an Australian study, all 
reported a similar reduction in need for 
surgical intervention.[11-14]
The pre-fibrinolysis treatment failure rate 
reported in our study (38.3%) is higher than 
the average rate (23.6%) found in a large 
meta-analysis of non-operative outcomes 
of 2 793 empyema cases published 
between 1982 and 2004.[15] Mortality and 
complication rates were 3.3% and 5.6%, 
respectively, similar to our study. The rate 
of treatment failure without fibrinloysis is 
variable, however, and has been reported 
in more recent studies to be as high as 
74 - 87%.[13,16] The higher than average 
treatment failure rate in the pre-fibrinolytics 
era in our study could be attributed to 
several factors. First, children in our cohort 
were considerably younger than those 
in most published studies (median age 
17.4 months v. 5 years).[15] Furthermore, 
the high prevalence of HIV infection and 
malnutrition in our cohort are probable 
contributing factors. Complicated or severe 
empyema is a consequence of the increased 
risk of severe invasive pneumococcal 
disease in children who are young, HIV-
infected or malnourished.[17] Higher rates of 
empyema in indigenous children compared 
with national populations have been 
reported elsewhere, suggesting that poverty, 
environmental exposure or malnutrition 
contribute to the pathogenesis and 
severity of empyema.[18] Secondly, referral 
for surgery in our practice was relatively 
early (median 7 days), increasing the 
likelihood of treatment failure as defined 
by our protocol. Lastly, 21.1% of patients 
were referred from other hospitals and 
represented complicated empyema cases. 
However, direct comparison of treatment 
failure rates between studies cannot be 
made, as definitions of treatment failure 
and indications for surgery differ between 
studies. 
The fibrinloysis treatment failure rate of 
9.6% in our study is comparable to other 
published reports. However, few prospective 
paediatric studies define failure of primary 
fibrinolysis as the primary outcome. Need 
for surgery is an important outcome in 
children, especially in settings such as sub-
Saharan Africa, where paediatric surgical 
resources are scarce. Two studies comparing 
fibrinolysis with VATS reported a fibrinolysis 
failure rate of 17% each.[19,20] Other 
prospective studies comparing fibrinolysis 
with normal saline or various doses of 
urokinase report fibrinolysis failure rates 
of 7 - 24%.[7,8,21] A meta-analysis published 
in 2005 calculated the average failure rate 
of 64 empyema cases treated with primary 
fibrinolysis to be 9.3%.[15]
Study limitations
The main limitation of this study is the 
use of a historical cohort as the control 
group. However, the prospective approach 
to patient recruitment, data collection and 
implementation of a standard fibrinolysis 
protocol strengthens the validity of our 
findings. Furthermore, the study was 
conducted at a single centre where senior 
medical staff and treatment protocols 
remained unchanged throughout the study 
period. The introduction of PCV7 in the 
national immunisation programme in 
2009 may have influenced the spectrum of 
empyema in our cohort. However, this is 
unlikely to have had an impact on the study 
findings, as very few patients had received 
Table 2. Baseline and clinical characteristics of patients with and without TPA treatment
TPA
(N=52)
No TPA
(N=47) p-value
Age (months), median (IQR) 21 (8 - 42) 17 (8 - 52) 0.9
HIV infected, n (%) 14/50 (28.0) 10/40 (25.0) 0.7
WAZ (<5 years), median (IQR) –1.08 (–2.4 - –0.3) –1.72 (–2.6 - –0.4) 0.3
Community referral, n (%) 42 (80.8) 37 (78.7) 0.8
Prior antibiotics, n (%) 24/52 (46.2) 24/40 (60.0) 0.1
No PCV, n (%) 43/47 (91.5) 46/46 (100.0) 0. 1
Streptococcus pneumoniae*, n (%) 11/52 (21.2) 10/47 (21.3) 0.9
Staphylococcus aureus*, n (%) 7/52 (13.5) 5/47 (10.6) 0.6
TB co-infection, n (%) 3/30 (10.0) 2/35 (5.7) 0.6
Total WCC (× 109/L), median (IQR) 18.5 (11.5 - 31.2) 24.4 (16.9 - 35.4) 0.07
Haemoglobin (g/dL), median 
(IQR) 
8.7 (7.2 - 10) (n=49) 9 (8 - 10) 
(n=46)
0.4
C-reactive protein (mg/L), mean 
(SD) 
258 (101)
(n=26)
193 (91)
(n=22)
0.02
Fluid lactate dehydrogenase (U/L), 
median (IQR) 
1 251 (596 - 5 040) 
(n=39)
2 743 (1 181 - 10 144) 
(n=14)
0.2
Fluid total protein (g/L), mean 
(SD) 
46 (17)
(n=36)
49 (19.5)
(n=14)
0.5
Underlying comorbidity, n (%) 7/52 (13.5) 6/47 (12.8) 0.9
WCC = white cell count.
*Combined blood and pleural fluid culture.
Table 3. Outcomes of patients treated with and without fibrinolysis
TPA
(N=52)
No TPA
(N=47)
Statistical 
significance
Surgery, n (%) 5 (9.6) 18 (38.3) RR (95% CI)
0.25 (0.1 - 0.6)
Days in hospital, median (IQR) 9.5 (7 - 16) 12 (10 - 20) p=0.08
Disease complications, n (%) 5 (9.6) 5 (10.6) NS
Treatment complications, n (%) 4 (7.7)* 2 (4.3)† NS
Mortality, n (%) 2 (3.8 ) 2 (4.2) NS
NS = not significant.
*2 episodes of intermittent occlusion due to catheter twisting; 1 blocked catheter needing replacement; 1 episode of severe 
pleural bleeding needing blood transfusion.
†1 incident where chest tube incorrectly inserted and needed replacement; 1 postoperative bronchopleural fistula.
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at least one dose of PCV7 because most were not an age eligible 
for immunisation when this was introduced into the programme 
and there was no catch-up campaign during this period. A 
second limitation is the potential bias towards delayed surgery 
and longer hospitalisation in the treatment group, but the similar 
time to surgery in both arms excludes this bias in our study. Lastly, 
although we attempted to exclude suspected or known TB empyema 
cases from treatment and analysis, a few children with TB empyema 
inadvertently received fibrinolysis because the diagnosis was not 
suspected at the time of presentation. These few cases were included 
in the analysis, as all were co-infected with a bacterial pathogen. 
Conclusion
The findings of our study have important implications for managing 
childhood empyema in settings where access to paediatric surgical 
expertise is limited. This study adds to the accumulating evidence 
for a beneficial role of primary fibrinolysis in childhood empyema. 
Fibrinolytics should be used for management of children with empyema 
who require drainage in LMIC settings. 
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